We are live on ! Find out more
KALV

KalVista Pharmaceuticals
KALV

Delisted

KALV was delisted on the 10th of June, 2026.

Back to rankings

89 hedge funds and large institutions have $364M invested in KalVista Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 31 increasing their positions, 28 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

16% more capital invested

Capital invested by funds: $314M → $364M (+$49.2M)

11% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 28

1.96% more ownership

Funds ownership: 97.2% → 99.16% (+2%)

8% less funds holding

Funds holding: 97 → 89 (-8)

42% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 19

Holders
89
Holders Change
-8
Holders Change %
-8.25%
% of All Funds
1.4%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.03%
New
11
Increased
31
Reduced
28
Closed
19
Calls
$1.66M
Puts
–
Net Calls
+$1.66M
Net Calls Change
+$1.64M

Top Buyers

Rank Fund Capital Flow
1
TCM
Tang Capital Management
California
+$9.31M
2
GPP
Great Point Partners
Connecticut
+$6.64M
3
WP
Woodline Partners
California
+$5.15M
4
DTC
Deep Track Capital
Connecticut
+$3.3M
5
PM
Prosight Management
Texas
+$2.58M

Top Sellers

Rank Fund Capital Flow
1
FM
Frazier Management
Washington
-$17.3M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$6.68M
3
DM
Deerfield Management
New York
-$4.95M
4
SFM
Sphera Funds Management
Israel
-$4.18M
5
EAM
Eventide Asset Management
Massachusetts
-$1.84M
Name Holding Trade Value Shares
Change 		Change in
Stake
AIP
76
Ameritas Investment Partners
Nebraska
$23K – – –
MLICM
77
Metropolitan Life Insurance Company (MetLife)
New York
$20.3K -$56K -3,900 -74%
Royal Bank of Canada
78
Royal Bank of Canada
Ontario, Canada
$20K -$51.7K -3,595 -72%
Rockefeller Capital Management
79
Rockefeller Capital Management
New York
$18K – – –
ACM
80
Aquatic Capital Management
Illinois
$3K -$33K -2,300 -92%
LC
81
Lindbrook Capital
California
$2K +$1.61K +112 New
Daiwa Securities Group
82
Daiwa Securities Group
Japan
$1K – – –
Osaic Holdings
83
Osaic Holdings
Arizona
$1K – – –
QCG
84
Quadrant Capital Group
Ohio
$1K – – –
AGM
85
Alpine Global Management
New York
$147 – – –
FM
86
Frazier Management
Washington
– -$17.3M -1,305,087 Closed
SFM
87
Sphera Funds Management
Israel
– -$4.18M -316,200 Closed
EAM
88
Eventide Asset Management
Massachusetts
– -$1.84M -138,821 Closed
ACM
89
Altium Capital Management
New York
– -$1.48M -111,834 Closed
Two Sigma Investments
90
Two Sigma Investments
New York
– -$1.29M -97,592 Closed
MP
91
Mangrove Partners
Connecticut
– -$1.22M -92,000 Closed
TCM
92
Tekla Capital Management
Massachusetts
– -$418K -31,594 Closed
JF
93
Jump Financial
Illinois
– -$349K -26,400 Closed
Russell Investments Group
94
Russell Investments Group
United Kingdom
– -$247K -18,705 Closed
TI
95
Trexquant Investment
Connecticut
– -$227K -17,131 Closed
CSS
96
Cubist Systematic Strategies
Connecticut
– -$225K -16,982 Closed
CC
97
Corton Capital
Ontario, Canada
– -$212K -15,991 Closed
SG Americas Securities
98
SG Americas Securities
New York
– -$158K -11,956 Closed
Manulife (Manufacturers Life Insurance)
99
Manulife (Manufacturers Life Insurance)
Ontario, Canada
– -$153 -11,560 Closed
Zurich Cantonal Bank
100
Zurich Cantonal Bank
Switzerland
– -$41K -3,085 Closed
1 2 3
4
5

KALV Hedge Fund Activity: Q1 2022 in Review

89 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q1 2022, worth a combined $364M — up 16% from $314M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of KALV and 11 opened new positions — a net loss of 8 holders — while 28 trimmed existing stakes and 31 added.

The largest buyer was Tang Capital Management, opening a new position worth an estimated $9.31M. The largest seller was Frazier Management, exiting entirely with an estimated $17.3M sold.

  • 89 institutional investors held KalVista Pharmaceuticals (KALV) as of Q1 2022, down from 97 in Q4 2021.
  • Funds reported $364M of KalVista Pharmaceuticals stock for Q1 2022, up 16% quarter-over-quarter.
  • 11 funds opened new KalVista Pharmaceuticals positions in Q1 2022 and 19 closed out, a net change of -8 holders.
  • The largest KalVista Pharmaceuticals buyer in Q1 2022 was Tang Capital Management, an estimated $9.31M added.
  • The largest KalVista Pharmaceuticals seller in Q1 2022 was Frazier Management, an estimated $17.3M sold.

Based on aggregated 13F filings for Q1 2022.